Center for Cancer Research, Purdue University, West Lafayette, IN, USA.
Regenstrief Center for Healthcare Engineering, Purdue University, West Lafayette, IN, USA.
J Gen Intern Med. 2019 Mar;34(3):435-442. doi: 10.1007/s11606-018-4785-z. Epub 2019 Jan 10.
Pain management racial disparities exist, yet it is unclear whether disparities exist in pain management in advanced cancer.
To examine the effect of race on physicians' pain assessment and treatment in advanced lung cancer and the moderating effect of patient activation.
Randomized field experiment. Physicians consented to see two unannounced standardized patients (SPs) over 18 months. SPs portrayed 4 identical roles-a 62-year-old man with advanced lung cancer and uncontrolled pain-differing by race (black or white) and role (activated or typical). Activated SPs asked questions, interrupted when necessary, made requests, and expressed opinions.
Ninety-six primary care physicians (PCPs) and oncologists from small cities, and suburban and rural areas of New York, Indiana, and Michigan. Physicians' mean age was 52 years (SD = 27.17), 59% male, and 64% white.
Opioids prescribed (or not), total daily opioid doses (in oral morphine equivalents), guideline-concordant pain management, and pain assessment.
SPs completed 181 covertly audio-recorded visits that had complete data for the model covariates. Physicians detected SPs in 15% of visits. Physicians prescribed opioids in 71% of visits; 38% received guideline-concordant doses. Neither race nor activation was associated with total opioid dose or guideline-concordant pain management, and there were no interaction effects (p > 0.05). Activation, but not race, was associated with improved pain assessment (ẞ, 0.46, 95% CI 0.18, 0.74). In post hoc analyses, oncologists (but not PCPs) were less likely to prescribe opioids to black SPs (OR 0.24, 95% CI 0.07, 0.81).
Neither race nor activation was associated with opioid prescribing; activation was associated with better pain assessment. In post hoc analyses, oncologists were less likely to prescribe opioids to black male SPs than white male SPs; PCPs had no racial disparities. In general, physicians may be under-prescribing opioids for cancer pain.
NCT01501006.
疼痛管理存在种族差异,但尚不清楚在晚期癌症的疼痛管理中是否存在差异。
研究种族对晚期肺癌医生疼痛评估和治疗的影响,并检验患者激活程度的调节作用。
随机现场试验。医生同意在 18 个月内接诊两名未事先通知的标准化患者(SP)。SP 扮演 4 个完全相同的角色——一位 62 岁的晚期肺癌伴疼痛控制不佳的男性患者,区别在于种族(黑种人或白种人)和角色(激活型或典型型)。激活型 SP 会提问、在必要时打断、提出要求和表达意见。
来自纽约、印第安纳和密歇根州的小城市、郊区和农村地区的 96 名初级保健医生(PCP)和肿瘤医生。医生的平均年龄为 52 岁(标准差=27.17),59%为男性,64%为白人。
开具(或未开具)的阿片类药物、每日总阿片类药物剂量(以口服吗啡当量表示)、符合指南的疼痛管理和疼痛评估。
SP 完成了 181 次秘密录音访问,这些访问的数据完整,可以用于模型协变量。医生在 15%的访问中发现了 SP。医生在 71%的访问中开具了阿片类药物;38%的人接受了符合指南的剂量。种族和激活程度均与总阿片类药物剂量或符合指南的疼痛管理无关,且无交互作用(p>0.05)。激活程度,但不是种族,与改善的疼痛评估相关(ß,0.46,95%CI 0.18,0.74)。在事后分析中,肿瘤医生(而非 PCP)不太可能为黑人 SP 开具阿片类药物(OR 0.24,95%CI 0.07,0.81)。
种族和激活程度均与阿片类药物的开具无关;激活程度与更好的疼痛评估相关。在事后分析中,与白人男性 SP 相比,肿瘤医生为黑人男性 SP 开具阿片类药物的可能性较低;而 PCP 则不存在种族差异。总的来说,医生可能为癌症疼痛开具的阿片类药物不足。
NCT01501006。